Predicting relapse in chronic spontaneous urticaria: A retrospective cohort study evaluating omalizumab withdrawal regimens.

Autor: Kucharczyk A; Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine - National Research Institute, Warszawa, Poland., Marczyk K; Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine - National Research Institute, Warszawa, Poland., Kucharczyk B; Medical Faculty I, Medical University of Warsaw, Warszawa, Poland., Plisko R; HTA Consulting, Kraków, Poland., Perkowska J; Department of Infectious Diseases and Allergology, Military Institute of Medicine - National Research Institute, Warszawa, Poland., Owczarek W; Department of Dermatology, Military Institute of Medicine - National Research Institute, Warszawa, Poland., Jahnz-Różyk K; Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.

Publikováno v: Allergy [Allergy] 2024 Sep; Vol. 79 (9), pp. 2554-2557. Date of Electronic Publication: 2024 Jun 24.

Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund.

Autor: Anczewska M; Instytut Psychiatrii i Neurologii, Warszawa., Balicki M; Pełnomocnik Ministra Zdrowia ds. reformy psychiatrii, Biuro ds. Pilotażu Narodowego Programu Ochrony Zdrowia Psychicznego., Droździkowska A; Departament Analiz i Strategii Ministerstwa Zdrowia, Warszawa., Gorczyca P; Śląski Uniwersytet Medyczny, Katowice., Janus J; Departament Analiz i Strategii Ministerstwa Zdrowia, Warszawa., Paciorek S; Departament Analiz i Strategii Ministerstwa Zdrowia, Warszawa., Plisko R; HTA Consulting, Kraków., Zięba M; Departament Analiz i Strategii Ministerstwa Zdrowia, Warszawa.

Publikováno v: Psychiatria polska [Psychiatr Pol] 2022 Aug 31; Vol. 56 (4), pp. 751-766. Date of Electronic Publication: 2022 Aug 31.

The Expiry of Humira ^® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.

Autor: Moorkens E; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.; Division of Public Health Pharmacy and Management, School of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden., Huys I; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Hoxha I; Department of Pharmacy, University of Medicine Tirana, Tirana, Albania., Malaj A; Department of Pharmacy, University of Medicine Tirana, Tirana, Albania., Keuerleber S; Austrian Social Insurance, Vienna, Austria., Stockinger S; Austrian Social Insurance, Vienna, Austria., Mörtenhuber S; Austrian Social Insurance, Vienna, Austria., Dimitrova M; Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria., Tachkov K; Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria., Vončina L; Faculty of Health Studies, University of Rijeka, Rijeka, Croatia., Palčevski VV; Faculty of Health Studies, University of Rijeka, Rijeka, Croatia., Achniotou G; Health Insurance Organization (HIO), Nicosia, Cyprus., Slabý J; State Institute for Drug Control, Prague, Czechia., Popelková L; State Institute for Drug Control, Prague, Czechia., Kohoutová K; State Institute for Drug Control, Prague, Czechia., Bartels D; Amgros, Copenhagen, Denmark., Laius O; State Agency of Medicines, Tartu, Estonia., Martikainen JE; Pharmaceuticals Pricing Board, Ministry of Social Affairs and Health, Helsinki, Finland., Selke GW; AOK Research Institute (WIdO), Berlin, Germany., Kourafalos V; National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece., Magnússon E; Ministry of Welfare, Reykjavik, Iceland., Einarsdóttir R; The National University Hospital of Iceland, Reykjavik, Iceland., Adams R; St James's Hospital, Dublin, Ireland., Joppi R; Clinical Research and Drug Evaluation Unit, Local Health Authority of Verona, Verona, Italy., Allocati E; Mario Negri Institute for Pharmacological Research (IRCCS), Milan, Italy., Jakupi A; UBT - Higher Education Institute, Prishtina, Kosovo., Viksna A; Department of Medicines and Medical Devices, The National Health Service, Riga, Latvia., Greičiūtė-Kuprijanov I; Ministry of Health of the Republic of Lithuania, Vilnius, Lithuania., Vella Bonanno P; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom., Suttorp V; Erasmus University Medical Center, Rotterdam, Netherlands., Melien Ø; Reviews and Health Technology Assessments, Norwegian Institute of Public Health, Oslo, Norway., Plisko R; HTA Consulting, Cracow, Poland., Mardare I; Public Health and Management Department, Faculty of Medicine, 'Carol Davila', University of Medicine and Pharmacy Bucharest, Bucharest, Romania., Meshkov D; V. A. Trapeznikov Institute of Control Sciences of Russian Academy of Sciences, Moscow, Russia., Novakovic T; ZEM Solutions, Belgrade, Serbia., Fürst J; Health Insurance Institute, Ljubljana, Slovenia., Zara C; Drug Area, Catalan Health Service, Barcelona, Spain., Marković-Peković V; Department of Social Pharmacy and Pharmacy Practice, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina., Grubiša N; Health Insurance Fund, Banja Luka, Bosnia and Herzegovina., Befrits G; Stockholm County Council, Stockholm, Sweden., Puckett R; NHS Greater Glasgow and Clyde, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Vulto AG; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Erasmus University Medical Center, Rotterdam, Netherlands.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2021 Jan 08; Vol. 11, pp. 591134. Date of Electronic Publication: 2021 Jan 08 (Print Publication: 2020).

PDB3 Epidemiology, Patient Burden and Related Costs of Obesity in China

Autor: Wojciechowski, P., Metz, L., Neoh, K., Caban, A., Gaweska, M., Gomulka, A., Plisko, R., Wladysiuk, M., Rys, P.

Publikováno v: Value in Health. 15(7)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c8ac220ea3561d6a9aa0198aca936e

PMD95 - Cost-Effectiveness Analysis Of Mechanical Thrombectomy In Acute Phase Of Ischemic Stroke (AIS)

Autor: Pochopien, M, Niesyczynski, G, Gorecki, M, Plisko, R

Publikováno v: In Value in Health October-November 2017 20(9):A589-A589